These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 10850749)
21. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287 [TBL] [Abstract][Full Text] [Related]
22. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. van Dongen MC; van Rossum E; Kessels AG; Sielhorst HJ; Knipschild PG J Am Geriatr Soc; 2000 Oct; 48(10):1183-94. PubMed ID: 11037003 [TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535 [TBL] [Abstract][Full Text] [Related]
24. Estimating the potential cost savings from the New York University Caregiver Intervention in Minnesota. Long KH; Moriarty JP; Mittelman MS; Foldes SS Health Aff (Millwood); 2014 Apr; 33(4):596-604. PubMed ID: 24711320 [TBL] [Abstract][Full Text] [Related]
25. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420 [TBL] [Abstract][Full Text] [Related]
26. Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications. Baladi JF; Bailey PA; Black S; Bouchard RW; Farcnik KD; Gauthier S; Kertesz A; Mohr E; Robillard A Clin Ther; 2000 Dec; 22(12):1549-61. PubMed ID: 11192146 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia. Versijpt J J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049 [TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V; Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236 [TBL] [Abstract][Full Text] [Related]
30. The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach. Wu G; Lanctôt KL; Herrmann N; Moosa S; Oh PI CNS Drugs; 2003; 17(14):1045-57. PubMed ID: 14594444 [TBL] [Abstract][Full Text] [Related]
31. Estimation of the family cost of private nursing home care versus home care for patients with dementia in Taiwan. Chiu L; Shyu WC Chang Gung Med J; 2001 Oct; 24(10):608-14. PubMed ID: 11771182 [TBL] [Abstract][Full Text] [Related]
32. IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's Disease. Gustavsson A; Jonsson L; Fillit H; Johansson G; Wimo A; Winblad B J Nutr Health Aging; 2010 May; 14(5):358-60. PubMed ID: 20424802 [TBL] [Abstract][Full Text] [Related]
33. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease. Lamb HM; Goa KL Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418 [TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651 [TBL] [Abstract][Full Text] [Related]
35. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. Getsios D; Blume S; Ishak KJ; Maclaine G; Hernández L Alzheimers Dement; 2012 Jan; 8(1):22-30. PubMed ID: 21420366 [TBL] [Abstract][Full Text] [Related]
36. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Wimo A; Winblad B; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Mastey V; Haglund A; Zhang R; Miceli R; Chin W; Subbiah P; Dement Geriatr Cogn Disord; 2003; 15(1):44-54. PubMed ID: 12457078 [TBL] [Abstract][Full Text] [Related]
37. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Hauber AB; Gnanasakthy A; Snyder EH; Bala MV; Richter A; Mauskopf JA Pharmacoeconomics; 2000 Apr; 17(4):351-60. PubMed ID: 10947490 [TBL] [Abstract][Full Text] [Related]
38. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Iskedjian M; Einarson TR Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573 [TBL] [Abstract][Full Text] [Related]
39. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study. Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645 [TBL] [Abstract][Full Text] [Related]
40. Reducing health care costs for dementia patients: estimating savings from a caregiver support program. Klug MG; Muus K; Volkov B; Halaas GW J Aging Health; 2012 Dec; 24(8):1470-85. PubMed ID: 23103454 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]